Biobehavioural approaches to prevention and treatment: A call for implementation science in obesity research

Kathryn A. Kaiser1,2 | Tiffany L. Carson2,3 | Emily J. Dhurandhar4 | William H. Neumeier5 | Michelle I. Cardel6

1 Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama
2 Nutrition Obesity Research Center, University of Alabama at Birmingham, Birmingham, Alabama
3 Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
4 Department of Kinesiology and Sport Management, Texas Tech University, Lubbock, Texas
5 United States Army Research Institute of Environmental Medicine, Natick, Massachusetts
6 Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida

Correspondence
Kathryn Kaiser, Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, RPHB 227, 1720 2nd Avenue South, Birmingham, AL 35294-0022, USA.
Email: kaker@uab.edu

Summary
Much progress has been made in the last 30 years in understanding the causes and mechanisms that contribute to obesity, yet widely available and successful strategies for prevention and treatment remain elusive at population levels. This paper discusses the biobehavioural framework and provides suggestions for applying it to enable greater progress in the science of obesity prevention and treatment, including an increased focus on implementation of science strategies. The objective is to promote a re-evaluation of current views about preventing and treating obesity within a unified biobehavioural framework. Further integration of research exploring how both behavioural and biological components interact is a critical step forward.

KEYWORDS
biobehavioural, implementation science, obesity

1 | INTRODUCTION

A 1982 Institute of Medicine (IOM) report titled Health and Behavior introduced the term “biobehavioural sciences” to embrace the many interacting disciplines that contribute to health outcomes.

The term biobehavioral sciences is used ... to refer to the panoply of basic, applied, and clinical sciences that contribute to an understanding of behavior. It naturally includes the behavioral sciences that conduct experimental analyses of animal and human conduct. It also includes such basic sciences as neurology, neurochemistry, endocrinology, and neuroanatomy, as well as the fields of psychology, ethology, sociology, and anthropology. ... All are part of the biobehavioral sciences.

Two years prior to this IOM report, the use of the term “biobehavioural” as related to obesity can be found.2 Decades of previous work2-10 have gone deeply into discovering detailed mechanisms to understand the contributing factors driving obesity and its complications, and by leveraging these discoveries from recent decades, scientists in our community can develop new and creative approaches using the biobehavioural framework. This mechanistic research has resulted in a broad but fragmented literature base that needs to be more fully integrated into a systems approach. Greater efforts are
needed to stimulate rapid evolution of obesity research and treatment approaches in all arenas, from basic science to public health, in recognition of the complexity and heterogeneity of this chronic disease.

Traditionally, behavioural scientists have strictly examined behavioural influences in the progression and treatment of obesity, while experts in basic sciences have investigated specific physiological processes. A push to integrate these two areas of research exists, and progress has been made; but thus far, obesity research has largely taken a behavioural12 or biological4 approach to the disease. Historically, this is due to a variety of factors including departmental and funding silos. New approaches are needed to encourage greater collaboration and interdisciplinary crosstalk among students and faculty. This is important because research exploring strategies to prevent or treat obesity as a behavioural condition or biological condition in isolation fails to acknowledge the complex and multifactorial aetiology including but not limited to genetics, viral exposure, foetal programming, epigenetics, medications, health behaviours, environment, gut microbiome, and psychosocial factors that impact obesity development.13,14 Research has demonstrated the adaptive and compensatory nature of energy balance,15,16 and by focusing on only one aspect of the metabolic system, the impact of other biobehavioural aspects that respond to minimize the perturbation may be missed. Thus, a milieu of physiological, behavioural, and environmental factors merits simultaneous scrutiny in order to identify opportunities for further study and intervention. Researchers and clinicians should promote a re-evaluation of current views about preventing and treating obesity within a unified biobehavioural framework. Further integration of research exploring how both behavioural and biological components interact is a critical step forward.

2 | VIEWING OBESITY AS A BEHAVIOURAL CONDITION VERSUS PHYSIOLOGICAL CONDITION ALONE IS NOT PRODUCTIVE

The first course of action for both obesity prevention and treatment is often behavioural in nature, and while to some degree this has worked in preventing and treating obesity-related comorbidities, its effectiveness in reducing obesity at a population level has been limited.17 The US Diabetes Prevention Program (US-DPP) not only demonstrated the potential of lifestyle changes as a strategy to prevent or delay the onset of type 2 diabetes (T2D) but also showed the limitations of a programme using a strictly behavioural approach for weight reduction, with an average of 4 kg of weight loss achieved over a 4-year period.18 Additionally, weight regain following cessation of clinical trials that target obesity with a behavioural approach is common.19

Another important study designed to use intensive lifestyle intervention (ILI) to reduce harms from T2D and cardiovascular events in older adults (>45 years old) with overweight was the Look AHEAD trial.20,21 The intervention (ILI compared with a diabetes support and education group) was a combination of meal replacements used to attain target energy intakes based on baseline weight, physical activity, and social support over a 4-year period, followed by a less intensive maintenance intervention consisting of biannual in-person contacts plus supplemental support as requested. Some have interpreted the outcomes of the Look AHEAD trial as “negative,” since it was stopped at 9.6 years for “futility” in finding no significant between-group differences, but in examining these results in light of more recent trials using pharmacological agents, there remains support for multimodal interventions for weight management and prevention of T2D.22,23

Behavioural approaches to weight loss may be difficult to maintain, as biological adaptations including reduced energy expenditure and increased appetite may occur. These physiological changes can influence adherence, planning of weight loss behaviours, fatigue, and motivation,24 creating a David-versus-Goliath imbalance where options that are resistant to homeostatic mechanisms are not available in the long run without increased risk for complications. Thus, therapies to ameliorate the intense physiological drive to reverse weight loss are needed.

One example is the use of pharmacotherapy; weight loss medication is currently recommended as an adjunct treatment to amplify outcomes of lifestyle modification.25 Weight loss medications primarily work to reduce hunger, appetite, and energy intake but may not be as effective without accompanying behavioural modification.26,27 Behavioural modification coupled with weight loss medication often results in equal or greater weight loss than stand-alone approaches.26-28 Regardless, modest weight regain has been observed in clinical trials that incorporate a combination of intensive dietary restriction with weight loss medications.26,27 This is likely because weight loss medications are typically prescribed to assist with the initial weight loss phase, but weight often increases when medication is discontinued, and behavioural strategies may not be enough to sustain long-term weight loss on their own.3

Bariatric surgery, which to date results in the highest average percentage of total weight loss, is another biobehavioural treatment that alters fundamental aspects of digestive and hormonal physiology; however, behaviour change remains critical for long-term success.29,31 as weight regain within 5 to 10 years is common.3 Both bariatric surgery and pharmacotherapy are commonly used in conjunction with behavioural therapy in treating T2D or hypertension but are less often used in cases of obesity that have not manifested comorbid conditions. Biobehavioural convergence as an approach to weight loss and obesity management may have the greatest impact on long-term obesity outcomes and thus prevents T2D and hypertension in many patients.

One reason a stand-alone behavioural treatment or a general, biologically rooted treatment for obesity such as pharmacotherapy may be limited in effectiveness is that multifactorial causes of obesity vary widely in each individual, causing heterogeneity in treatment effect. Twin, genetic, and developmental origins studies of obesity, along with inflammation, infection, and microbiome factors, show individual effects.32 Yet these potential contributors are not currently considered in prevention or treatment for obesity. No two people have become obese in exactly the same way. Conversely, it is difficult to predict which mode of therapy will be most effective, making a case for integrated, multidisciplinary treatment strategies, and to study the effects of various treatment modalities in younger people.33-35
3 | OTHER DISEASES ARE NOT TREATED THE SAME WAY

A strategy of approaching obesity from either a biological or a beha-
vioural perspective differs from other chronic diseases, such as as-
thma. Although asthma and obesity are two different conditions, some par-
allels allow comparison of standard approaches to disease manage-
ment. Both are emergent phenotypes based on developmental,
environmental, behavioural, and physiological interactions, are
associated with morbidity and mortality, and adversely impact
quality of life. Both asthma and obesity disproportionately impact
racial/ethnic minorities and individuals of lower socio-economic sta-
tus. Nonetheless, approaches to understanding and treating obe-
sity are very different than those for asthma.

The asthma care model includes components that may serve to
guide our approach to understanding and treating obesity. For exam-
ple, physicians are trained to treat asthma in medical school, but phy-
sicians often have little formal training in the aetiology of obesity or
how to treat it. Thus, providers report a lack of confidence in
discussing weight management with patients despite a large evi-
dence base. Obesity treatment is not often mentioned as part of a
routine patient visit despite obesity diagnosis. Like obesity, asthma
management benefits from early and regular surveillance by parents,
school staff, and primary care physicians and merits lifelong care. Re-
ognizing the importance of a multifactorial approach for asthma con-
trol, the Centers for Disease Control and Prevention released
EXHALE, a technical package that incorporates behavioural, envi-
ronmental, pharmacological, and policy strategies across multiple sec-
tors to improve and maximize asthma control in all ages.

Instead of putting the onus on asthma sufferers to "just not do
anything to trigger an attack," which is like telling a person with obe-
sity to "just eat less and move more," the holistic approach sug-
gested in the EXHALE program addresses factors at individual
(behavioural and physiologic), environmental, and policy levels to man-
age asthma over the life course. Approaches to understanding and
treating obesity must become more interdisciplinary and move from
an acute treatment model to a chronic disease model where lifelong
treatment is expected and provided, to increase the impact of what
has been accomplished to date.

4 | ISSUES AND POTENTIAL SOLUTIONS

The obesity community should focus on the critical issue of the hetero-
genicity of both causes of obesity and treatment responses, which
demands new study recruitment and design approaches. Although stud-
ies that reflect treatment response heterogeneity may not be originally
designed for this purpose, data investigations have consistently
observed treatment response heterogeneity in behavioural weight loss
interventions. This response heterogeneity discreditst a one-size-fits-
all approach to weight loss while adding credence for more tailored,
precise, and cause-specific weight loss approaches. Acknowledging sex
and age differences is particularly important, as well as risk factors in
special populations. In particular, much progress has been made in
biobehavioural prevention and treatment strategies for pregnant
women, infants, and children. However, much work remains for
groups with complex psychosocial risk factors. When heteroge-
neous responses are acknowledged, the community of researchers
and clinicians may address potential prevention and treatment targets;
and these factors would ideally be included in future studies to inform
precision obesity medicine. A new narrative focused on the personal-
ization of treatment based on multifactorial biobehavioural factors,
rather than one of individual responsibility, is urgently needed.

More than 90 potential contributors have been associated with
weight gain and obesity, including factors such as genetics, diet, psy-
chosocial influences, lack of physical activity, and environmental
dynamics. Thus, in order to prevent and treat obesity, a
biobehavioural approach towards obesity as a chronic medical condi-
tion requiring lifelong medical monitoring and care is most appropri-
ate. Given the pervasive emphasis on an individual's responsibility to
"eat less and move more," obesity prevention and treatment require
a shift in cultural values and social norms.

One such shift must change the conduct of research and provision of
clinical care for individuals with obesity, ensuring a biobehavioural
approach wherever people live, work, and play. Broadening the
scope of research and teaching students and trainees to include biolog-
ical and behavioural interactional contributions to obesity could open
additional strategies and clinical avenues that yield better treatment
outcomes. Compared with other chronic diseases, there are relatively
few ubiquitously used treatment strategies, and some remain unfunded
or underfunded by insurance payers and underutilized by clinicians.

One way to address these issues is to include implementation sci-
ence methods that rigorously test demonstrably effective interven-
tions in resource-intensive, randomized controlled trials to determine
how best to implement them in clinical- or community-based settings.
Implementation science is the scientific study of methods to promote
the systematic uptake of research findings and other evidence-based
practices into routine practice, and hence, to improve the quality of
effectiveness of health services. Implementation and obesity scien-
tists share the same goal: ensuring that patients receive the best qual-
ity of care rooted in evidence-based practice. However, to date, there
has been little merging of implementation science in treating obesity.
A PubMed search of "implementation science" and "obesity" retrieved
only 53 studies (accessed March 5, 2019), 24 of which focused on
obesity or weight gain; the earliest was published in 2012. This shows
that the field of implementation science for obesity has room for addi-
tional growth. However, implementation science has been used to
improve real-world treatment outcomes for other complex multifac-
torial disease states. Where this shows success is when clinic-based
programmes are moved into the public health realm.

One approach that aligns well with obesity is translating prevention
programmes for T2D. Several large randomized controlled trials con-
ducted in the United States, Finland, China, and India have come to
the same conclusion; we can reduce the incidence of T2D by 29% to
58% in high-risk populations using lifestyle interventions, with generally
successful maintenance up to 20 years later. Once effectiveness is
demonstrated in clinical trials, the research focus needs to move towards understanding why clinical trials were effective and how these programmes may work when implemented in real-world settings. The US-DPP, initially a resource-intensive model tested in randomized controlled trials, has been optimized to a less intensive curriculum delivered by non-medical personnel, which has lowered the overall costs of the programme without compromising effectiveness. Others have suggested that it is critical to have all health-care providers involved in obesity management and for them to not just focus on body size but health improvement for the whole patient. This requires a paradigm shift for clinical practice customs in many countries.

In an implementation science framework, using the simplest and most practical measures customized to individual study and patient needs is a key. One promising development in obesity research is standardizing measurement across studies and developing core measures through a project known as Accumulating Data to Optimally Predict Obesity Treatment (ADOPT), which published six papers in Obesity in Spring, 2018. By focusing on standardized activities and measures to prevent weight gain, patients with obesity may manage potential health harms individually, with a better understanding of maintaining lifestyle modifications long term.

5 | SUMMARY

This commentary is not an extensive literature review or a succinct summary of all aspects of biobehavioural research to date. Rather, it is an attempt to add voices to those of others who call for increased concerted action to build on this large body of research in a way that moves obesity prevention and patient care forward. These perspectives are not new or novel yet seem to be lost among thousands of mechanistic studies that have illuminated the complexity of the problem more than they have pointed to simple solutions.

Biobehavioural research aims to direct obesity prevention and treatment through a broader, overall approach rather than narrowed scopes of biology or behaviour. A more robust biobehavioural model of obesity research integrating the complex interactions between biological, behavioural, and environmental factors is needed for moving the field forward, and this requires a shift in norms of training and research design. This must include public health and other prevention approaches, which we have not fully discussed here, in addition to increased engagement in implementation science. Costs and ethics associated with challenges for public health interventions require creative problem solving. Guidance of obesity research through the biobehavioural spectrum using implementation science will allow building on the foundation of previous research while creating interdisciplinary synergies to an ongoing epidemic.

ACKNOWLEDGEMENTS

The authors are grateful to Myles S. Faith, PhD, and Gareth R. Dutton, PhD, for the suggestions on an earlier version of this paper and to the anonymous reviewers whose insightful comments and suggestions were invaluable.

CONFLICT OF INTEREST

No conflict of interest was declared.

FUNDING INFORMATION

No direct funding was provided in the support of this work, although the authors have present or past associations with the Nutrition Obesity Research Center at the University of Alabama at Birmingham, grant no. P30DK056336. The opinions expressed in this article are solely those of the authors and do not necessarily reflect the positions of their respective universities or the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Army or Department of Defense.

AUTHOR CONTRIBUTIONS

All authors were involved in writing the paper and had final approval of the submitted and published versions.

ORCID

Kathryn A. Kaiser  https://orcid.org/0000-0002-6258-4369
Tiffany L. Carson  https://orcid.org/0000-0002-8180-4523
Emily J. Dhurandhar  https://orcid.org/0000-0001-7633-5083
William H. Neumeier  https://orcid.org/0000-0002-5588-0477
Michelle I. Cardel  https://orcid.org/0000-0002-9395-8618

REFERENCES

1. IOM (Institute of Medicine). Health and Behavior: Frontiers of Research in the Biobehavioral Sciences. Washington, DC: National Academy Press; 1982.
2. Hartman LM. A biobehavioral model of obesity. Psychoter Psychosom. 1980;33:205-213.
3. Schultes B. Pharmacological interventions against obesity: current status and future directions. Visc Med. 2016;32:347-351.
4. MacLean PS, Blundell JE, Mennella JA, Batterham RL. Biological control of appetite: a daunting complexity. Obesity (Silver Sprin, Md). 2017;25:58-S16.
5. Velapati SR, Shah M, Kuchkuntla AR, et al. Weight regain after bariatric surgery: prevalence, etiology, and treatment. Curr Nutri Reports. 2018;7:329-334.
6. Bae SA, Fang MZ, Rustgi V, Zarbl H, Androulakis IP. At the interface of lifestyle, behavior, and circadian rhythms: metabolic implications. Front Nutr. 2019;6:132. https://doi.org/10.3389/fnut.2019.00132
7. Greco EA, Lenz A, Migliaccio S, Gessani S. Epigenetic modifications induced by nutrients in early life phases: gender differences in metabolic alteration in adulthood. Front Genet. 2019;10:795. https://doi.org/10.3389/fgene.2019.00795
8. Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Trans Med. 2019;7:393-399.
9. Wang Y, Guo X, Lu X, Mattar S, Kassab G. Mechanisms of weight loss after sleeve gastrectomy and adjustable gastric banding: far more than just restriction. Obesity (Silver Sprin, Md). 2019;27:1776-1783.
Belalcazar LM, Ballantyne CM. Looking back at Look AHEAD through the lens of recent diabetes outcome trials. J Diabetes Complications. 2017;31:578-582.

Bhuchali AL, Garg RK, Garg M, et al. The role of dietary and physical activity interventions in the management of type 2 diabetes. J Hum Nutr Diet. 2019;32:626-631.

Bhushan S, Gupta T, Pandey R, et al. The role of dietary counseling in the management of type 2 diabetes. J Clin Diabetol Metab. 2019;9:1-5.

Bhandari A, Dhawan A, Sood S, et al. The role of lifestyle modifications in the management of type 2 diabetes. J Diabetes Metab. 2018;9:1-7.

Biner R, Biber K, Wirth S, et al. The role of diabetes education and self-management in the management of type 2 diabetes. J Diabetes Educ. 2019;43:168-174.

10. Zhang Z, Mocanu V, Cai C, et al. Impact of fecal microbiota transplantation on obesity and metabolic syndrome—a systematic review. Nutrients. 2019;11:2291-2306.

11. Zerhouni E. Medicine. The NIH roadmap. Science. 2003;302:63-72.

12. Brownell KD, Kersh R, Ludwig DS, et al. Personal responsibility and obesity: a constructive approach to a controversial issue. Health Affairs (Project Hope). 2010;29:379-387.

13. Steinbeck KS, Lister NB, Gow ML, Baur LA. Treatment of adolescent obesity. Nat Rev Endocrinol. 2018;14:331-344.

14. Srivastava G, Fox CK, Kelly AS, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. Obesity. 2019;27:190-204.

15. Dhurandhar EJ, Kaiser KA, Dawson JA, Alcorn AS, Keating KD, Allison DB. Predicting adult weight change in the real world: a systematic review and meta-analysis accounting for compensatory changes in energy intake or expenditure. Int J Obes (2005). 2015;39:1181-1187.

16. Hall KD, Heymsfield SB, Kemnitz JW, Klein S, Schoeller DA, Speakman JR. Energy balance and its components: implications for body weight regulation. Am J Clin Nutr. 2012;95:998-994.

17. National Center for Health Statistics (U.S.). NCHS data brief Vol. 219, November 2015. Hyattsville, MD. Available at: https://www.cdc.gov/nchs/data/databriefs/db219.pdf.

18. Knowler WC, Barrett J, Dorn D, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring, Md). 2006;14:737-752.

19. Maclan P, Bergouignan A, Cornier MA, Jackman MR. Biology’s response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol. 2011;301:R581-R600.

20. Wadden TA, West DS, Delahanty L, et al. The Look AHEAD study: randomized controlled trial of orlistat for weight loss and prevention of weight regain for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610-628.

21. Ryan DH, Reseland EA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610-628.

22. Belalcazar LM, Ballantyne CM. Looking back at Look AHEAD through the lens of recent diabetes outcome trials. Circulation. 2017;135:720-723.

23. Kones R, Rumana U, Merino J. Exclusion of ‘nonRCT evidence’ in guidelines for chronic diseases—is it always appropriate? The Look AHEAD study. Curr Med Res Opin. 2014;30:2009-2019.

24. MacLean PS, Wing RR, Davidson T, et al. NIH working group report: innovative research to improve maintenance of weight loss. Obesity (Silver Spring, Md). 2015;23:7-15.

25. Leahy LG. Medication-assisted weight loss in the age of obesity. J Psychosoc Nurs Ment Health Serv. 2017;55:21-26.

26. Sjostrom L, Rissanen A, Andersson T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998;352:167-172.

27. Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30:27-32.

28. Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293-316.

29. Hsu LK, Benotti PN, Dwyer J, et al. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med. 1998;60:338-346.

30. Odom J, Zalesin K, Washington T, et al. Behavioral predictors of weight regain after bariatric surgery. Obes Surg. 2010;20:349-356.

31. Sarver DB, Wadden TA, Fabricatore AN. Psychosocial and behavioral aspects of bariatric surgery. Obes Res. 2005;13:639-648.

32. The Obesity Society. Potential contributors to obesity to 2015. Available from: https://highglogindexdownload.s3.amazonaws.com/OBE557Y/ 04d47f0-37d5-434e-b24d-08a32dfd9f19f/uploadImages/potent ial_contributors_to_obesity_2015_infographic.jpg. Accessed: 11/16/ 2018.

33. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115:1447-1463.

34. Looney SM, Raynor HA. Behavioral lifestyle intervention in the treatment of obesity. Health Serv Insights. 2013;6:15-31.

35. Cardel MI, Jastreboff AM, Kelly AS. Treatment of adolescent obesity in 2020. JAMA. 2019. epub 2019/10/01:322:1707-1708. https://doi. org/10.1001/jama.2019.14725.

36. Scott HA, Wood LG, Gibson PG. Role of obesity in asthma: mechanisms and management strategies. Curr Allergy Asthma Rep. 2017;17:53. https://doi.org/10.1007/s11882-017-0719-9.

37. Gilliland FD. Outdoor air pollution, genetic susceptibility, and asthma management: opportunities for intervention to reduce the burden of asthma. Pediatrics. 2009;123:S168-5173.

38. Abdellaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Annals of Trans Med. 2017;5:161-172.

39. D’Amato G, Vitale C, Molino A, et al. Asthma-related deaths. Multidisciplinary Resp Med. 2016;11:37-42. https://doi.org/10.1186/s40248- 016-0073-0.

40. Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obes Rev. J Int Assoc Study Obesity. 2001;2:219-229.

41. Lusk AT, Chipp ES, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2:544-552. e541-542.

42. Cox TL, Ard JD, Beasley TM, et al. Examining the association between body mass index and weight related quality of life in black and white women. Appl Res Qual Life. 2012;7:309-322.

43. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284-2291.

44. Forno E, Celedon JC. Asthma and ethnic minorities: socioeconomic status and beyond. Curr Opin Allergy Clin Immunol. 2009;9:154-160.

45. Forno E, Celedon JC. Health disparities in asthma. Am J Respir Crit Care Med. 2012;185:1033-1035.

46. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;1-8.

47. Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socioeconomic status in adults: United States 1988-1994 and 2005-2008. Hyattsville, MD: National Center for Health Statistics; 2010.

48. Stanford FC, Johnson ED, Claridy MD, Earle RL, Kaplan LM. The role of obesity training in medical school and residency on bariatric surgery knowledge in primary care physicians. Int J Family Med. 2015;2015: 841249. http://dx.doi.org/10.1155/2015/841249.
87. Sutin AR, Boutelle K, Czajkowski SM, et al. Accumulating Data to Opti-
mally Predict Obesity Treatment (ADOPT) core measures: psychosocial
domain. Obesity (Silver Spring, Md). 2018;26:S45-S54.

88. Truong W, Aronne LJ. ADOPT: obesity treatment reaches level of
maturity with its own collaborative initiative and resource. Obesity (Sil-
ver Spring, Md). 2018;26:S5.

How to cite this article: Kaiser KA, Carson TL, Dhurandhar EJ,
Neumeier WH, Cardel MI. Biobehavioural approaches to pre-
vention and treatment: A call for implementation science in
obesity research. Obes Sci Pract. 2020;6:3–9. https://doi.org/
10.1002/osp4.384